Albemarle vs Avient
ALB and AVNT side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALB and AVNT compare
Albemarle is the larger company, worth 2.7 times as much as Avient ($10.7B against $3.9B).
On earnings, Avient is cheaper: it trades at 23.2× trailing earnings, against 337× for Albemarle.
Albemarle grew revenue faster over the last twelve months (18.3% versus 2.4% for Avient).
Avient keeps more of each dollar of sales as profit, with a net margin of 5.1% compared with 3.8% at Albemarle.
Both pay dividends: Albemarle yields 1.8% and Avient 2.6%.
Albemarle scores higher on the StockData Score (16 against 12 for Avient), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALB | AVNT |
|---|---|---|
| Size and price | ||
| Market cap | $10.7B | $3.9B |
| Share price | $91.00 | $42.84 |
| Change, 1 year | −7.0% | 34.3% |
| Change, 5 years | −66.6% | −26.0% |
| Beta (5Y) | 1.68 | 1.36 |
| Employees | 7,800 | 9,000 |
| StockData Score | ||
| Total score | 16 (better) | 12 |
| Valuation score | 4 (better) | 2 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 4 (better) | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 337× | 23.2× (better) |
| P/S | 1.8× | 1.2× (better) |
| P/B | 1.0× (better) | 1.6× |
| EV/EBITDA | 12.6× | 10.7× (better) |
| P/FCF | 8.0× (better) | 20.6× |
| FCF yield | 12.5% (better) | 4.9% |
| Fair value | $117.07 | $48.97 |
| Margin of safety | 22.3% (better) | 12.5% |
| Growth | ||
| Revenue growth (TTM) | 18.3% (better) | 2.4% |
| Revenue growth, 5Y average | 10.4% (better) | 8.0% |
| Net income growth (TTM) | – | 43.0% |
| EPS growth (TTM) | – | 43.4% |
| EPS growth, 5Y average | – | −9.3% |
| Profitability | ||
| Gross margin | 23.8% | 31.7% (better) |
| Operating margin | 4.3% | 9.5% (better) |
| Net margin | 3.8% | 5.1% (better) |
| FCF margin | 22.7% (better) | 5.7% |
| Return on equity | 2.2% | 7.1% (better) |
| Return on invested capital | 1.1% | 6.1% (better) |
| Financial health | ||
| Debt / equity | 0.18 (better) | 0.77 |
| Net debt / EBITDA | 0.27 (better) | 2.87 |
| Current ratio | 2.09 (better) | 1.90 |
| Altman Z-score | 2.24 (better) | 1.54 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.8% | 2.6% (better) |
| Payout ratio | 85.0% | 58.7% |
| Years of dividend growth | 16 (better) | 15 |
| Dividend growth, 5Y average | 1.0% | 5.8% (better) |
| Shareholder yield | 1.8% | 2.6% (better) |
| Ownership | ||
| Held by institutions | 98.3% | 105% |
| Held by insiders | 0.35% | 0.86% |
| Insider net buying, 12 months | −$7.4M | – |
| Short interest, % of float | 10.0% | 5.1% |
Go deeper
- ALB stock overview
- ALB income statement
- ALB valuation and score
- AVNT stock overview
- AVNT income statement
- AVNT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.